---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-012915"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:50:33.112667+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# iMDx submits GraftAssureDx to FDA; Q4 revenue $1.1M, net loss $23.0M

## Summary
- Submitted GraftAssureDx kidney transplant test to FDA on March 25; expects 150-day review and authorization this year.
- Full year 2025 revenue $4.1M (up from $1.9M); Q4 revenue $1.1M, net loss $23.0M ($0.72/share).
- Adjusted Q4 net loss $8.7M ($0.27/share); R&D expenses rose 50% sequentially to $5.8M due to FDA submission.
- Impaired oncology intangibles $14.6M ($11.7M DetermaCNI, $2.9M DetermaIO) to focus on transplant.
- Appointed Dr. Nick Ioannou as VP Medical Affairs; completed $26M financing in February for heart expansion.

## SEC filing metadata
- accession: 0001493152-26-012915
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315226012915/0001493152-26-012915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315226012915/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-012915
- JSON: https://secwatch.observer/filing/0001493152-26-012915.json
- Plain text: https://secwatch.observer/filing/0001493152-26-012915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.